Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.
Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.
Surmodics' (SRDX) receipt of the FDA's positive formal feedback regarding its PMA application for the SurVeil DCB looks promising.